To better understand the role of inflammation in COVID-19, we established the Michigan Medicine COVID-19 Cohort (M2C2). M2C2 is a funded and ongoing cohort which has currently enrolled over 1500 adult patients (≥18 years) with severe COVID-19 admitted at the University of Michigan. The purpose of M2C2 is to define the in-hospital course of these patients and understand the role of inflammation as a determinant of organ injury and outcomes in COVID-19.
The Michigan Medicine COVID-19 Cohort is a prospective observational cohort study of patients
hospitalized specifically for COVID-19 at the University of Michigan Health System in Ann
Arbor. Medical records of all consecutive patients with a positive SARS-CoV-2 are reviewed,
and patients with confirmed SARS-CoV-2 infection but not primarily admitted for COVID-19 were
excluded.
Biologic samples of patients enrolled in M2C2 were collected, and clinical characteristics
including in-hospital outcomes were characterized in detail.
Biomarkers measured include, but not be limited to, soluble urokinase plasminogen activator
receptor (suPAR), high sensitive C reactive protein (hs-CRP), brain natriuretic protein
(BNP), high sensitive troponin T (hsTnT), interleukin 6 (IL-6), osteopontin, a2-antiplasmin.
Diagnostic Test: Biomarkers of inflammation
Biomarkers were measured on blood samples collected within 48 hours of admission
Inclusion Criteria:
- Confirmed SARS-CoV-2 infection
- Hospitalized primarily for the treatment of COVID-19
Exclusion Criteria:
- SARS-CoV-2 positive but hospitalized for non-COVID-19 reasons
University of Michigan
Ann Arbor, Michigan, United States
Investigator: Pennelope K Kunkle
Contact: 734-936-3500
penegonz@umich.edu
Investigator: Salim S Hayek, MD
Salim Hayek, MD
734-936-3500
shayek@umich.edu
Penney Kunkle
penegonz@umich.edu
Salim Hayek, MD, Principal Investigator
University of Michigan